Pharmaceutical Technology5 天
Retifanlimab by Incyte for Endometrial Cancer: Likelihood of Approval
Retifanlimab (Zynyz) is a humanized IgG4 kappa monoclonal antibody produced in Chinese hamster ovary cells. It is formulated as solution for intravenous route of administration. Zynyz is indicated for ...
Pharmaceutical Technology5 天
Retifanlimab by Incyte for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of ...
Retifanlimab is under clinical development by Incyte and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.